Each month the CSF Steering Committee selects the latest published original articles on RA, PsA, and axSpA, focusing on those with data on therapeutic interventions and those that have clinical impact.
RA Literature Highlights – October 2022
Baricitinib, Tofacitinib, JAK Inhibition, JAK Inhibitor Switching, Tofacitinib
PsA Literature Highlights – September 2022
Upadacitinib, Secukinumab, Guselkumab, Risankizumab, MCID
RA Literature Highlights – September 2022
IL-6 Inhibition, Tofacitinib, JAK Inhibition, Upadacitinib, Sarilumab, Olokizumab, Baricitinib, Filgotinib
PsA Literature Highlights – August 2022
Secukinumab, Bimekizumab, Risankizumab, CHOICE, SELECT-PsA-1, SELECT-PsA-2
PsA Single Slide Summaries - July
Bimekizumab, Guselkumab, Ixekizumab, Apremilast, Secukinumab, General Health Outcomes